About Symvivo

Symvivo has developed a novel bacterial-based gene delivery platform specific for solid tumors, referred to as our bacTRL™ technology.  bacTRL™ dramatically out-performs existing gene delivery technologies, providing superior rates of gene delivery and solid tumor selectivity.  This technology has the potential to change the immuno-oncology field, enabling the development of new, highly efficacious and safe technologies.  In addition, extending the use of preexisting immuno-therapies into other solid tumor indications.